Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2 A Randomized Clinical Trial
Emily Y Chew, Traci E Clemons, Glenn J Jaffe, Charles A Johnson, Sina Farsiu, Eleonora M Lad, Robyn Guymer, Philip Rosenfeld, Jean-Pierre Hubschman, Ian Constable, Henry Wiley, Lawrence J Singerman, Mark Gillies, Grant Comer, Barbara Blodi, Dean Eliott, Jiong Yan, Alan Bird, Martin Friedlander
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2019
Supported by the Lowy Medical Research Institute, La Jolla, California; and Neurotech Pharmaceuticals, Inc, Cumberland, Rhode Island, which provided the Neurotech-501 implants producing ciliary neurotropic factor (CNTF). The funding organization (Lowy Medical Research Institute) and the sponsor (Neurotech Pharmaceuticals, Inc) were consulted for design and conduct of the study. The collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication were the responsibilities of the research team, the MacTel Project investigators.